

## **Repligen Extends Long Term Supply Agreement with Cytiva for Affinity Ligands**

**WALTHAM, MA, September 3, 2021** -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has extended through 2025 a long-term supply agreement with Cytiva for the manufacture of ligands at the Company's facilities in Waltham, MA and Lund, Sweden. The agreement maintains Repligen as a key strategic supplier to Cytiva.

Kola Otitoju, Repligen's SVP Strategy and Business Development, said, "We are very pleased to extend this partnership with Cytiva and continue our 30+ year partnership. Ligands are a very important part of our overall business strategy, where our focus is on providing these products reliably at large scale from multiple sites. By offering flexibility for strategic customers like Cytiva, we continue to differentiate ourselves in the bioprocessing marketplace."

Affinity ligands are the critical component of chromatography media that enable the affinity purification of monoclonal antibody-based biologic drugs. There are currently more than 120 monoclonal antibodies that have received U.S. FDA regulatory approval and more than 600 are at various stages of clinical development.

###